Zacks Investment Research on MSN1 小时
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
来自MSN1 个月
Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition
In fact, Novartis already expects U.S. competition for Entresto, Tasigna and Promacta to begin in mid-2025. Tasigna is a cancer drug, while Promacta treats low blood platelets. The latter drugs ...